In particular, the administration of tumor necrosis factor-α (TNF-α) inhibitors, often chosen to treat patients with recurrent or refractory TAK (discussed below), would be expected to increase the risk of TB development by up to 25-fold [18]. The gene discussed is TNF; the disease is tuberculosis.